Significant events during the fourth quarter
- Net sales increased by 11% (20% adjusted for currency changes) to
SEK 185 m (166). - EBITDA margin was 25% (32%).
-
Acquisition of shares and strategic partnership in
Vital Nutrients Holdings . The acquisition amounted toUSD 6 m and represents slightly less than 10% ownership. - Publication of major study confirms using Probi Defendum® has a positive effect on common colds.
Significant events during full-year 2020
- Net sales increased by 15% (17% adjusted for currency changes) to
SEK 717 m (626). - The EBITDA margin was 27% (29%).
-
In 2020, Covid-19 led to increased demand for probiotics in the
Americas , while at the same time causing greater sales volatility in EMEA and APAC. -
The Board of Directors proposes that the 2021 Annual General Meeting establish a dividend of
SEK 1.10 (1.00) per share corresponding toSEK 12.5 m (11.4) for the 2020 financial year.
CEO Comments
A strong 2020 gives us confidence
2020 was a strong year for
We finished the year with a convincing final quarter and net sales of
During Q4, work began on a number of new studies in bone health, stress and female health. A new important study in digestive health was started on the Chinese market, which is
The upgrade of the manufacturing site in the US, which took place throughout 2020, has now largely been completed. In the coming months, the focus will be on streamlining production and we expect to see the effects of these investments during the second half of 2021.
In October, we launched a clearer profile for our product portfolio. Within ClinBacÔ, we have collected our premium segment with our most scientifically validated bacterial strains, and LiveBacÒ is the brand name for our range of safe bacterial strains as a complement to, or as individual ingredients in, our customers' products.
In 2020, we communicated new, more ambitious long-term growth and profitability targets. Despite challenges in the outside world, we are fully focused on our goals and expect to achieve these in 2021 and beyond. During the year, we increased our collaboration with one of our largest customers in the
In summing up 2020, I can state that we are in an excellent position to maintain our growth through both existing and new customers and through more expanded collaborations and acquisitions. Together with all our skilled employees, I look forward to making
Tom Rönnlund
CEO
Invitation to teleconference
Contacts
Tom Rönnlund, CEO, Tel: +46 (0)46 286 89 40, Email: trd@probi.com
This information is information that
https://news.cision.com/probi/r/q4-2020--strong-finish-to-a-successful-year,c3282492
https://mb.cision.com/Main/1556/3282492/1369745.pdf
(c) 2021 Cision. All rights reserved., source